MANKIND vs SUNPHARMA: Stock Comparison

Mankind Pharma Limited vs Sun Pharmaceutical Industries Ltd

Live data: 22 July 2026, 2:37 PM IST • Source: NSE and company filings

Sun Pharmaceutical Industries Ltd is the larger company by market capitalisation. Sun Pharmaceutical Industries Ltd shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Mankind Pharma Limited and Sun Pharmaceutical Industries Ltd on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, MANKIND is more favourable on 2 of 13 scored metrics and SUNPHARMA on 11These counts are context-free and are not an overall rating.

Key Differences

Market Cap
SUNPHARMA is the larger company
₹4.66 L Cr vs ₹1.05 L Cr
P/E Ratio
SUNPHARMA has a lower P/E
41.01x vs 55.54x
P/B Ratio
SUNPHARMA has a lower P/B
5.63x vs 6.52x
EPS
SUNPHARMA has higher earnings per share
₹47.87 vs ₹46.34
Dividend Yield
SUNPHARMA has a higher dividend yield
0.82% vs 0.04%
Revenue Growth (TTM YoY)
SUNPHARMA has faster revenue growth
12.8% vs 11.8%
EPS Growth (TTM YoY)
MANKIND has faster EPS growth
31.7% vs 25.6%
Qtr Sales Growth
SUNPHARMA has stronger quarterly sales growth
12.8% vs 11.8%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricMANKINDSUNPHARMA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricMANKINDSUNPHARMA
Live Price₹2,540.7₹1,940
Day Change-1.5%-1.12%
Volume2.57 L13.17 L
52-Week High₹2,690₹1,966.5
52-Week Low₹1,909.7₹1,548
Distance from 52W High-5.55%-1.35%

Valuation

MetricMANKINDSUNPHARMA
Market Cap₹1.05 L Cr₹4.66 L Cr
P/E Ratio55.54x41.01x
P/B Ratio6.52x5.63x
EPS₹46.34₹47.87
Book Value₹395.2₹348.31
Dividend Yield0.04%0.82%

Growth

MetricMANKINDSUNPHARMA
Revenue Growth (TTM YoY)11.8%12.8%
EPS Growth (TTM YoY)31.7%25.6%
Qtr Sales Growth11.8%12.8%
Qtr Profit Growth34.2%13.6%

Profitability & Leverage

MetricMANKINDSUNPHARMA
ROE13.1%16%
ROCE13.5%20.5%
Net Margin13.34%18.56%
Operating Margin25.3%28.2%
Debt to Equity0.39x0.06x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricMANKINDSUNPHARMA
Promoter Holding72.66%54.48%
FII Holding10.24% 1.1 pp14.53% 1.4 pp
DII Holding14.46% 1.21 pp22.18% 1.07 pp
Public Holding2.64% 0.11 pp8.81% 0.33 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Mankind Pharma Limited and Sun Pharmaceutical Industries Ltd.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.